Form 4: Blueprint Medicines Director Albers Exercises Options and Sells Shares
SEC Form 4 Filing
Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp. on September 9, 2024, according to a Form 4 filing with the SEC.
Summary
- On September 9, 2024, Jeffrey W. Albers, a director of Blueprint Medicines Corp., exercised stock options to acquire 10,000 shares of common stock at a price of $36.05 per share.
- Albers then sold 11,968 shares at a weighted average price of $85.86, with individual transactions ranging from $85.59 to $86.58 per share.
- He also sold 7,734 shares at a weighted average price of $85.12, with individual transactions ranging from $84.78 to $85.56 per share.
- Following these transactions, Albers beneficially owns 157,557 shares of Blueprint Medicines Corp.
- The transactions were executed according to a pre-arranged trading plan adopted on May 8, 2024, under Rule 10b5-1.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather reports factual information.
Industry Context
Insider transactions are routinely monitored and reported to the SEC. The use of a 10b5-1 trading plan allows insiders to sell shares over a period of time, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- It's common for executives and directors to have stock options as part of their compensation packages.
- The exercise of options and subsequent sale of shares is a typical way for insiders to realize value from their equity compensation.
- The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations, similar to practices at companies like Amgen, Regeneron, and Vertex.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The director's actions could be interpreted as a sign of confidence or lack thereof, although the pre-arranged trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 02/16/2017 | Date the stock option was granted. |
| 05/08/2024 | Date the trading plan was adopted. |
| 09/09/2024 | Date of the transactions (option exercise and share sales). |
| 09/11/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.